Among the patients with CMR abnormalities (n = 155), 74 of them (47.7%) received NSAIDs (for chronic pericardial effusion), 81 (52.3%) ARB, 25 (16.1%) ARB/HCT, 6 (3.9%) ACE inhibitor, 68 (24.5%) beta blockers, 15 (5.4%) aldosterone antagonists (for cardiac impairment), and 71 (25.5%) H2-receptor blocker therapy. This evidence concerns the gene ACE and pericardial effusion, chronic.